JP2021522795A - ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 - Google Patents

ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 Download PDF

Info

Publication number
JP2021522795A
JP2021522795A JP2020561780A JP2020561780A JP2021522795A JP 2021522795 A JP2021522795 A JP 2021522795A JP 2020561780 A JP2020561780 A JP 2020561780A JP 2020561780 A JP2020561780 A JP 2020561780A JP 2021522795 A JP2021522795 A JP 2021522795A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020561780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522795A5 (enExample
Inventor
ラビンドラ クマール，
ラビンドラ クマール，
ダイアン エス． サコ，
ダイアン エス． サコ，
ロズリーヌ カストンギー，
ロズリーヌ カストンギー，
ズー−シン クオ，
ズー−シン クオ，
Original Assignee
アクセルロン ファーマ インコーポレイテッド
アクセルロン ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ インコーポレイテッド, アクセルロン ファーマ インコーポレイテッド filed Critical アクセルロン ファーマ インコーポレイテッド
Publication of JP2021522795A publication Critical patent/JP2021522795A/ja
Publication of JP2021522795A5 publication Critical patent/JP2021522795A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020561780A 2018-05-03 2019-05-02 ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 Pending JP2021522795A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666548P 2018-05-03 2018-05-03
US62/666,548 2018-05-03
US201862779992P 2018-12-14 2018-12-14
US62/779,992 2018-12-14
PCT/US2019/030475 WO2019213446A1 (en) 2018-05-03 2019-05-02 NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2021522795A true JP2021522795A (ja) 2021-09-02
JP2021522795A5 JP2021522795A5 (enExample) 2022-05-13

Family

ID=68386156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561780A Pending JP2021522795A (ja) 2018-05-03 2019-05-02 ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用

Country Status (6)

Country Link
US (2) US12168683B2 (enExample)
EP (1) EP3788067A4 (enExample)
JP (1) JP2021522795A (enExample)
AU (1) AU2019262143A1 (enExample)
CA (1) CA3099325A1 (enExample)
WO (1) WO2019213446A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024534643A (ja) * 2021-09-27 2024-09-20 ゾエティス・サービシーズ・エルエルシー 抗ＴＧＦβ１、２、３抗体及びその治療的使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019262139A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
US12527839B2 (en) 2019-11-05 2026-01-20 Acceleron Pharma Inc. Treatments for systemic sclerosis
US20240277807A1 (en) * 2021-06-11 2024-08-22 Acceleron Pharma Inc. Actrii proteins and uses thereof
KR102971166B1 (ko) * 2022-12-09 2026-06-01 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521311A (ja) * 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
JP2016037488A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
WO2016164089A2 (en) * 2015-04-06 2016-10-13 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
JP2017506217A (ja) * 2014-02-10 2017-03-02 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113185A1 (en) * 2007-03-19 2008-09-25 National Research Counsil Of Canada Antagonists of ligands and uses thereof
RU2678117C2 (ru) * 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
HK1225742A1 (zh) * 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
EP3522912A4 (en) 2016-10-05 2020-10-14 Acceleron Pharma Inc. HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521311A (ja) * 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
JP2017506217A (ja) * 2014-02-10 2017-03-02 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害
JP2016037488A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
WO2016164089A2 (en) * 2015-04-06 2016-10-13 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024534643A (ja) * 2021-09-27 2024-09-20 ゾエティス・サービシーズ・エルエルシー 抗ＴＧＦβ１、２、３抗体及びその治療的使用

Also Published As

Publication number Publication date
CA3099325A1 (en) 2019-11-07
EP3788067A4 (en) 2022-01-19
US20210380663A1 (en) 2021-12-09
EP3788067A1 (en) 2021-03-10
AU2019262143A1 (en) 2020-11-26
US20250333477A1 (en) 2025-10-30
US12168683B2 (en) 2024-12-17
WO2019213446A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
JP7246618B2 (ja) ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
RU2748278C2 (ru) Композиции и способы лечения легочной гипертензии
EP3929211B1 (en) Alk4:actriib heteromultimers and uses thereof
JP7058606B2 (ja) 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト
JP2021054839A (ja) シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
JP7159148B2 (ja) Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
CN110036025A (zh) 变体ActRIIB蛋白及其用途
US20170137503A1 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
JP2024113195A (ja) Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
US20250333477A1 (en) Novel binders of tgfb-superfamily ligands and uses thereof
JP2021526835A (ja) 二機能性および三機能性融合タンパク質およびその使用
US20250109179A1 (en) MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF
JP2023528709A (ja) バリアントａｃｔｒｉｉｂタンパク質およびその使用
HK1248735B (en) Alk7:actriib heteromultimers and uses thereof
HK1248734B (en) Alk4:actriib heteromultimers and uses thereof
HK40004171A (en) Actrii antagonists for use in increasing immune activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114